Retrospective Study
Copyright ©The Author(s) 2021.
World J Gastroenterol. Feb 14, 2021; 27(6): 513-522
Published online Feb 14, 2021. doi: 10.3748/wjg.v27.i6.513
Table 1 Basic information of patients with nonerosive reflux disease
Item
PPI
WMT
P value
Female68
Age (median; IQR, yr)58.5 (53, 67.25)62 (55, 67)0.526
Duration (median; IQR, mo)48 (15, 144)24 (6, 60)0.218
BMI (median; IQR, kg/m2)21.63 (19.13, 24.38)24.24 (22.58, 25.43)0.079
Table 2 Symptom scores and remission time before and after treatment in the two groups
Group
PPI (n = 12)
WMT (n = 15)
P value1
Pre-GERDQ (median; IQR)12 (9, 13.75)12 (10, 12)0.746
Post-GERDQ (median; IQR)11 (8.25, 13.5)7 (7, 8)0.004
Intra-group, P value20.4770.003
Pre-RDQ (median, IQR)26 (18, 33)23 (16, 25)0.203
Post-RDQ (median, IQR)20.5 (12.75, 26)8 (6, 12)0.003
Intra-group, P value0.0050.002
Remission time (median, IQR; mo)2 (0, 4)8 (3, 17)0.002
Table 3 Clinical responses to washed microbiota transplantation in patients with nonerosive reflux disease
Item

WMT, n = 15
Remission1, n14 (93.3)
Remission after the first course of WMT, n13 (86.7)
Remission after the first course of FMT until the end of the study, n10 (66.7)
No remission after the first course of WMT, n2 (13.3)
Recurrence after remission, n2 (13.3)
Side effects of WMT treatment2, nNo 14 (93.3)
Yes1 (6.70)
Table 4 Use of proton pump inhibitors in nonerosive reflux disease patients
Items
PPI
WMT
Continuous use before treatment (n)No reduction after treatment34
Reduction after treatment50
Withdrawal after treatment30
Usage as needed before treatment (n)No reduction after treatment04
Reduction after treatment22
Withdrawal after treatment22
Table 5 Results of examining the function of the intestinal mucosal barrier in the washed microbiota transplantation group
Item
Lipopolysaccharide
Diamine oxidase
D-lactate
Pre-treatment (median, IQR)7.5 (3.6, 10.4)4.1 (3.2, 6.5)8.9 (7.6, 11.8)
Post-treatment (median, IQR)10.1 (1.0, 23.6)7.7 (2.3, 13.54)16.3 (7.7, 18.3)
P value10.4010.2630.208